Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 106,113

Document Document Title
WO/2015/055771A1
The present invention relates toaminotetralineand aminoindane derivatives of the formula (I) (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetralineand ami- noi...  
WO/2015/058053A1
The present invention encompasses methods of treating a subject who stutters. The methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount o...  
WO/2015/055698A1
The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said ...  
WO/2015/056771A1
[Problem] To provide a compound useful as a pharmaceutical composition for prevention and/or treatment of diseases such as schizophrenia. [Solution] The inventors developed the present invention upon investigating a pharmaceutical compos...  
WO/2015/053614A1
Present invention discloses an oil palm composition for use in prevention or treatment of Alzheimer's disease. The composition is useful in impeding formation of neurotoxic peptide. Present invention can be used in preparation of a medic...  
WO/2015/054358A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2015/052105A1
The present invention relates to a compound of general formula (I) wherein R is hydrogen or tritium; F is fluoro or 18fluoro; or to a pharmaceutically acceptable acid addition salt. Compounds of formula I include 2-(6-fluoro-pyridin-3-yl...  
WO/2015/051448A1
Provided herein are compositions and methods for reducing neurogeneration in a patient suffering from Parkinson's Disease, comprising administration of a composition comprising CoQ10 and polyoxyethanyl-a-tocopherylsebacate (PTS). The com...  
WO/2015/053624A3
The invention relates to means and methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-m RNA ...  
WO/2015/051738A1
Crystalline particle of tofacitinib citrate, process for the preparation of a crystalline particle of tofacitinib citrate, pharmaceutical composition, substantially pure amorphous form of tofacitinib citrate, process for preparing the su...  
WO/2015/054005A1
The present invention provides, among other things, methods and compositions for treating brain-derived neurotrophic factor (BDNF)-related conditions. In some embodiments, the methods include administering to a subject suffering form or ...  
WO/2015/053402A1
In order to provide a compound capable of treating or preventing spinocerebellar degeneration, analysis was undertaken using screening, etc., using a spinocerebellar degeneration type 1 (SCA1) fly model. As a result, RPA1, PNKP, XRCC3, X...  
WO/2015/052226A1
The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.  
WO/2015/051747A1
Disclosed in the present invention are a pramipexole extended release tablet and a preparation method and use thereof, wherein the extended release tablet consists of pramipexole or a pharmaceutically acceptable salt thereof, two or more...  
WO/2015/054059A2  
WO/2015/053561A1
A composition, a dietary supplement or a treatment method of the present invention has a remarkable cranial nerve protection effect and simultaneously has a sensorimotor function recovery promotion effect and a body weight increasing eff...  
WO/2015/054103A1
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be us...  
WO/2015/054063A1
Aspects of the invention include methods of treating withdrawal syndrome by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a non-sedative amount of dexmedetomidine to a subject diagn...  
WO/2015/051766A1
The present invention relates to amide substituted indazoles and benzotriazoles which are inhibitors of the enzyme poly (ADP-ribose) polymerase (PARP), previously known as poly (ADP-ribose) synthase and poly (ADP-ribosyl) transferase. Th...  
WO/2015/054062A2  
WO/2015/052610A1
Provided herein are antagonists (I) of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof. (Formula I)  
WO/2015/053337A1
The purpose of the present invention is to provide: a foodstuff, etc., containing a histidine having a novel composition and/or form; a foodstuff, etc., having a novel function on the basis of the histidine; and, more specifically, a foo...  
WO/2015/050835A1
There is provided mild cognitive impairment (MCI) and/or Alzheimer's disease (AD) biomarkers and related methods for assisting in distinguishing between AD and MCI status in a subject, and additionally or alternatively, for assisting in ...  
WO/2015/051152A1
Methods for treating and reducing the progression of neurodegenerative diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention reduce or deplete neutrophil/myeloid cells in the region of th...  
WO/2015/049616A1
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, met...  
WO/2015/051362A1
Multifunctional chelators, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.  
WO/2015/050383A1
The present invention relates to: a method for regulating autophagy comprising a step of making cells come into contact with p62 protein, the ZZ domain of the p62 protein, or an N-end rule ligand interacting with residues 128-163 in the ...  
WO/2015/049677A1
The present invention discloses a method of identifying agents that affect human astrocytes functionality using ex-vivo differentiated pluripotent stem cells (PSC). In addition, the use of human progenitor astrocytes or human astrocytes ...  
WO/2015/050212A1
[Problem] The present invention addresses the problem of providing novel compounds that have T-type voltage-gated calcium channel-blocking activity and are useful particularly in treating pain, chronic kidney disease, and atrial fibrilla...  
WO/2015/049574A1
4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological d...  
WO/2015/051043A1
The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. (Ia); as described in the specificat...  
WO/2015/050984A1
Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by w...  
WO/2015/049608A1
The present invention describes the use of propylparaben, a widely known antimicrobial, for decreasing neuronal injury induced by Status epilepticus. An objective of the invention is the administration of propylparaben immediately after ...  
WO/2015/051188A1
Probes which target diffuse and fibrillar forms of amyloid beta (Aβ) are described. These probes demonstrate high initial brain penetration and facile clearance from non-targeted regions. The agents can be used to image amyloid quantita...  
WO/2015/051259A1
Disclosed are compositions and methods for administering an NMDA receptor antagonist to a patient. The compositions may be administered orally, buccally, sublingually or rectally.  
WO/2015/050235A1
 The purpose of the present invention is to identify patients resistant to known HSP90 inhibitors and to provide a novel therapeutic for treating patients who have become resistant to known HSP90 inhibitors. As a means of solving this ...  
WO/2015/044251A1
The invention concerns substances for the prophylaxis and treatment of a neurodegenerative disease not based on a protein folding disorder. It further concerns substances for stabilizing photoreceptors.  
WO/2015/043567A1
The invention relates to amyloid-beta-binding peptides and the use thereof for the therapy and diagnosis of Alzheimer's dementia.  
WO/2015/044095A1
The present invention relates to compounds of general formula (I) wherein R1 is lower alkyl or lower alkyl substituted by halogen; R2, R3 are hydrogen or tritium; or to a pharmaceutically acceptable acid addition salt. The compounds may ...  
WO/2015/043398A1
Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acce...  
WO/2015/044963A9
The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a proce...  
WO/2015/043473A1
Provided herein are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors and pharmaceutical uses thereof, particularly 6,8-dioxabicyclo [3.2.1] octane derivatives represented by Formula (I), or ph...  
WO/2015/046563A1
Without increasing the size of an existing capsule product, a further health-promoting component is sealed into the soft capsule while maintaining the DHA and EPA content of the existing product. A fish oil concentrated such that the con...  
WO/2015/046403A1
The purpose of the present invention is to provide a compound that exerts a strong analgesic action against on pain, in particular, against neuropathic pain and/or fibromyalgia syndrome. The present invention provides a cyclic amine deri...  
WO/2015/044952A3
Disclosed is a tramadol hydrochloride and paracetamol composition, comprising: about 2.5 to about 5 percent by weight of tramadol hydrochloride; about 25 to about 30 percent by weight of paracetamol; about 1.25 to about 1.75 percent by w...  
WO/2015/043404A1
The present invention relates to a salt of (-)-huperzine-a, which is prepared from the reaction of huperzine-a and a corresponding acid. The huperzine-a salt is selected from huperzine-a hydrochloride, hydrobromide, sulfate, phosphate, n...  
WO/2015/043511A1
Disclosed are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors, intermediates or preparation processes thereof, and pharmaceutical uses thereof, especially glucopyranosyl derivatives represent...  
WO/2015/047902A1
The present invention provides novel trimethylammonium compounds, of the Formula: (I) methods of making these compounds, methods of using the compounds for preparation of tau imaging agents, and preparation of tau imaging agent formulati...  
WO/2015/048245A1
The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of var...  
WO/2015/042706A1
The present invention relates to interleukin-4 receptor-binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 or interleukin-13 protein moiety joined to an anti-apoptot...  

Matches 351 - 400 out of 106,113